Email: Password:
| Forgot Password
Nav_logo

A free online accredited CPD program for healthcare professionals

Biologics in Pharmacy Practice: Addressing Your Patients’ Frequently Asked Questions

1.50 Canadian Council On Continuing Education In Pharmacy (CCCEP) CEU(s)

Program available online until: August 02, 2019



This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP)
for 1.50 CEU(s).

Biologics: The future is here. How ready are you to answer your patients’ questions?

Content/Programs/CaseStudy/BiologicsBiosimilarsFAQs_9225/assets/images/LP.jpg

Biologics have revolutionized the treatment of many diseases, including oncology, rheumatoid arthritis, inflammatory bowel disease and psoriasis. Many of these therapies (e.g. TNF-alpha inhibitors) target parts of the immune system that causes inflammation. More and more patients can now enjoy a better quality of life because the treatment dramatically increased efficacy with a relatively acceptable safety profile. 

This program will address some of the most frequently asked questions by patients treated with biologics for inflammatory diseases. The goal is to prepare you for managing these common concerns when they occur in practice.

Planning Committee

  • Pierre-Marc Gervais, PharmD..
  • Mark Hazeltine, MD, FRCP(C), FACP.
  • Michael Boivin, B.Pharm., CDE, CTE, CTH.
  • John Papastergiou, BScPhm, RPh.

Learning Objectives

After completion of this program, participants will be able to:

  • Discuss options to address the proper management of common clinical situations related to the use of biologic drugs for immune-mediated inflammatory diseases
  • Demonstrate improved communication with patients on biologics and thus empower them in the self-management of their disease
  • Apply relevant and current guidelines in management of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease and psoriasis when communicating with patients on optimal risks and benefits of biologics
  • Recognize the difference between biologics and biosimilars

Ask the Expert: Michael Boivin, B.Pharm., CDE, CTE, CTH

  • Why should pharmacists care about biologics and specialty drugs?
  • How important is interprofessional collaboration?
  • How do you address concerns of patients who take biologic therapy who have an infection?
  • How do you best address the importance of immunization in patients treated with biologics?
  • What are the main discussion points with a patient with a rheumatologic disease who is of reproductive age?
  • What are the main points in management of a preoperative patient who is on biologics?
  • How to best address patient’s concern about biologics and risk of cancer?
  • How to address the issue of alcohol in patients who ask about MTX and alcohol?
  • What are the main issues with biosimilars from a pharmacist’s perspective?
  • How to best address the issue of adherence?
Content/Programs/CaseStudy/BiologicsBiosimilarsFAQs_9225/assets/images/MichaelBoivin.jpg

mdBriefCase is the practical choice to earn your CPD Credits

Icon of multiple pages

20+ therapeutic areas

100+ programs each year.

Icon of multiple pages

Quality, accredited content

Developed by leading specialists and peer-reviewed by experts at respected institutions.

Icon of multiple pages

Online convenience

Save time and money.

Join 45,000+ of your colleagues

Create your free account today